The kallikrein-kinin pathway is dysregulated in HAE1

Uncontrolled plasma kallikrein leads to excessive bradykinin production2

TAKHZYRO's mechanism of action on plasma kallikren inhibits the release of bradykinin, an enyzme known to cause HAE attacks
TAKHZYRO's mechanism of action on plasma kallikren inhibits the release of bradykinin, an enyzme known to cause HAE attacks

Figure adapted from Valerieva et al, Bender et al, and Csuka et al.3-5
C1-INH=C1 esterase inhibitor; cHMWK=cleaved high molecular weight kininogen; FXII=factor XII; FXIIa=factor XIIa; HMWK=high molecular weight kininogen; PKa=activated plasma kallikrein.

Style
inner-content-contained, section-no-top-margin, section-no-bottom-margin, section-no-top-padding, footnote, moa-container

An established mAb targeting the inhibition of plasma kallikrein to reduce the release of bradykinin1

TAKHZYRO provides targeted inhibition of plasma kallikrein, a critical regulator of bradykinin, known to cause HAE attacks1

Uncontrolled plasma kallikrein leads to excessive bradykinin production, which can cause HAE attacks
Uncontrolled plasma kallikrein leads to excessive bradykinin production, which can cause HAE attacks

Figure adapted from Valerieva et al, Bender et al, and Csuka et al.3-5
C1-INH=C1 esterase inhibitor; cHMWK=cleaved high molecular weight kininogen; FXII=factor XII; FXIIa=factor XIIa; HMWK=high molecular weight kininogen; PKa=activated plasma kallikrein.

Style
inner-content-contained, footnote, section-no-top-margin, section-no-bottom-margin, section-no-top-padding, moa-container

See efficacy and safety across all 3 studies

Explore the results of the HELP study, the HELP open-label extension study, and the SPRING study.

EXPLORE TAKHZYRO DATA

Style
inner-content-contained, background-lavender-light, section-no-top-margin, section-no-bottom-margin

References: 1. Takhzyro. Prescribing information. Dyax Corp; 2023. 2. Banerji A, Busse P, Shennak M, et al. N Engl J Med. 2017;376(8):717-728. doi:10.1056/NEJMoa1605767. 3. Valerieva A, Longhurst HJ. Front Allergy. 2022;3:952233. doi: 10.3389/falgy.2022.952233. 4. Bender L, Weidmann H, Rose-John S, et al. Front Immunol. 2017;8:1115. doi:10.3359/fimmu.2017.01115. 5. Csuka D, Veszeli N, Imreh É, et al. Orphanet J Rare Dis. 2015;10:132. doi:10.1186/s13023-015-0351-5.

style
inner-content-contained, section-references, section-no-top-margin, section-no-bottom-margin
https://main--takeda-eds-sites-takhzyro--onetakeda.hlx.page/hcp/fragments/isi
Style
Inner-content-contained, section-no-margin
id
important-safety-information